NewAmsterdam Pharma Company N.V. (NAMS)
(Delayed Data from NSDQ)
$16.39 USD
-0.61 (-3.59%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $16.33 -0.06 (-0.37%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for NewAmsterdam Pharma Company NV falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 340 | 462 | 1 | 1 | -99,999 |
Receivables | 0 | 0 | 0 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 6 | 10 | 0 | 1 | NA |
Total Current Assets | 347 | 472 | 1 | 2 | NA |
Net Property & Equipment | 0 | 0 | 0 | 0 | NA |
Investments & Advances | 0 | 0 | 138 | 138 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 88 | 0 | 0 | NA |
Deposits & Other Assets | 0 | 0 | 0 | 0 | NA |
Total Assets | 347 | 560 | 140 | 140 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 17 | 19 | 0 | 0 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 11 | 0 | 0 | 0 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 22 | 18 | 0 | 0 | NA |
Total Current Liabilities | 50 | 37 | 0 | 0 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 1 | 5 | 5 | 5 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 8 | 7 | 141 | 130 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 59 | 50 | 146 | 135 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 10 | 631 | 0 | 0 | NA |
Capital Surplus | 591 | 0 | 0 | 5 | NA |
Retained Earnings | -317 | -126 | -6 | 0 | NA |
Other Equity | 4 | 5 | 0 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 288 | 510 | -6 | 5 | NA |
Total Liabilities & Shareholder's Equity | 347 | 560 | 140 | 140 | NA |
Total Common Equity | 288 | 510 | -6 | 5 | 0 |
Shares Outstanding | 82.40 | 81.50 | 17.70 | 4.70 | NA |
Book Value Per Share | 3.50 | 6.26 | -0.36 | 1.06 | 0.00 |
Fiscal Year End for NewAmsterdam Pharma Company NV falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 431 | 481 | 340 | -99,999 | -99,581 |
Receivables | 0 | 0 | 0 | NA | NA |
Notes Receivable | 0 | 0 | 0 | NA | NA |
Inventories | 0 | 0 | 0 | NA | NA |
Other Current Assets | 15 | 7 | 6 | NA | 6 |
Total Current Assets | 445 | 488 | 347 | NA | 424 |
Net Property & Equipment | 0 | 0 | 0 | NA | 0 |
Investments & Advances | 0 | 0 | 0 | NA | NA |
Other Non-Current Assets | 0 | 0 | 0 | NA | NA |
Deferred Charges | 0 | 0 | 0 | NA | NA |
Intangibles | 1 | 0 | 0 | NA | 89 |
Deposits & Other Assets | 0 | 0 | 0 | NA | 0 |
Total Assets | 447 | 488 | 347 | NA | 514 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | NA | NA |
Accounts Payable | 5 | 9 | 17 | NA | 23 |
Current Portion Long-Term Debt | 0 | 0 | 0 | NA | NA |
Current Portion Capital Leases | 0 | 0 | 0 | NA | NA |
Accrued Expenses | 10 | 10 | 11 | NA | NA |
Income Taxes Payable | 0 | 0 | 0 | NA | NA |
Other Current Liabilities | 30 | 41 | 22 | NA | 19 |
Total Current Liabilities | 45 | 60 | 50 | NA | 42 |
Mortgages | 0 | 0 | 0 | NA | NA |
Deferred Taxes/Income | 0 | 0 | 1 | NA | 3 |
Convertible Debt | 0 | 0 | 0 | NA | NA |
Long-Term Debt | 0 | 0 | 0 | NA | NA |
Non-Current Capital Leases | 0 | 0 | 0 | NA | NA |
Other Non-Current Liabilities | 13 | 8 | NA | 8 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | NA | NA |
Total Liabilities | 59 | 77 | 59 | NA | 53 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | NA | NA |
Common Stock (Par) | 11 | 11 | 10 | NA | 664 |
Capital Surplus | 822 | 807 | 591 | NA | NA |
Retained Earnings | -450 | -411 | -317 | NA | -212 |
Other Equity | 4 | 4 | 4 | NA | 9 |
Treasury Stock | 0 | 0 | 0 | NA | NA |
Total Shareholder's Equity | 387 | 412 | 288 | NA | 460 |
Total Liabilities & Shareholder's Equity | 447 | 488 | 347 | NA | 514 |
Total Common Equity | 387 | 412 | 288 | 0 | 100,459 |
Shares Outstanding | 89.90 | 89.70 | 82.40 | 82.30 | 82.30 |
Book Value Per Share | 4.31 | 4.59 | 3.50 | 0.00 | 1,220.65 |